Biopharmaceutical NewsWeek 39     Acquisitions /Mergers/Joint-ventures September 22, 2014  Merck buys Sigma-Aldrich for $17 billion Drugs and chemicals maker Merck KGaA agreed to acquire U.S. company Sigma-Aldrich for $17 billion in cash to boost its lab supplies business. The deal, which was approved by Sigma-Aldrich's management, will see Merck acquire all shares for $140 apiece […]

Biopharmaceutical NewsWeek # 8       Business September 16, 2014  AstraZeneca and Eli Lilly partner up on Alzheimer’s drug Under the terms of the agreement, Lilly will pay AstraZeneca up to $500 million in development and regulatory milestone payments. The companies will share all future costs and revenues post-launch. The compound in question, AZD3293, […]

Biopharmaceutical NewsWeek #7   Business September 01, 2014  Ablynx signs a deal with China's Eddingpharm Ablynx of Belgium has signed a deal to license one of its investigational rheumatoid arthritis drug ozoralizumab to China's Eddingpharm. Ozoralizumab is a next-generation nanobody TNF-alpha. Eddingpharm is getting rights to the compound and will be responsible for the clinical […]

Biopharmaceutical NewsWeek # 6 Acquisitions /Mergers/Joint-ventures August 25, 2014  Roche buys InterMune for $8.3 billion Roche is to acquire InterMune Inc, based in Brisbane, California, for $8.3 billion in cash to gain access to that company portfolio that includes pirfenidone, for the treatment of idiopathic pulmonary fibrosis. Pirfenidone is an already marketed product in the […]